OCS — Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: CH
- Exchange: NASDAQ Global Market
- Employees: 49
- Website: https://oculis.com
Latest SEC filings for OCS
- 6-K — 2026-06-01
- 6-K — 2026-05-14
- 6-K — 2026-03-04
- F-3ASR — 2026-03-04
- 20-F — 2026-03-04
- 6-K — 2026-03-03
- 424B3 — 2025-12-01
- 6-K — 2025-11-10
- F-3 — 2025-11-10
- 424B5 — 2025-10-31
Latest OCS news
- — Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis (GlobeNewswire Inc.)
- — Oculis kynnir ný lífmerkisgögn (e. Biomarker Data) úr fasa 2 ACUITY-rannsókninni sem styðja enn frekar taugaverndandi möguleika Privosegtor við sjóntaugabólgu (GlobeNewswire Inc.)
- — Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting (GlobeNewswire Inc.)
- — Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki (GlobeNewswire Inc.)
- — Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day (GlobeNewswire Inc.)
- — Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS (globenewswire.com)
- — Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS (globenewswire.com)
- — Oculis Announces Resignation of Lionel Carnot from Board of Directors (globenewswire.com)
- — After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS) (zacks.com)
Educational tool only — not investment advice.